Literature DB >> 19176690

Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age.

Didier Pinquier1, Arnaud Gagneur, Laurent Balu, Olivier Brissaud, Christèle Gras Le Guen, Isabelle Hau-Rainsard, Olivier Mory, Georges Picherot, Loïc De Pontual, Jean-Louis Stephan, Peter Maple, Judith Breuer, Marie Aubert, Evelyne Caulin, Claudine Sana, Pierre Pradat, Benoît Soubeyrand, Philippe Reinert.   

Abstract

Varicella is a widespread disease of childhood resulting from primary infection with varicella-zoster virus (VZV). The objective of this study was to determine the kinetics of the decline of maternal anti-VZV antibodies in French infants between birth and the age of 15 months in order to estimate the duration of passively acquired maternal anti-VZV immunoglobulin G (IgG). This prospective multicenter study was conducted between October 2005 and January 2007 in the pediatric wards and/or pediatric emergency units of seven French hospitals scattered throughout the country. The level of anti-VZV IgG antibodies in serum was measured by a time-resolved fluorescence immunoassay (TRFIA) (the threshold considered positive is 150 mIU/ml). A total of 345 infants were included. Seventy-seven percent of mothers reported a history of varicella. A rapid decline in the prevalence of anti-VZV antibodies was observed during the first few months of life, with the mean antibody titer decreasing from 536 mIU/ml at birth and through 1 month to below the 150-mIU/ml threshold at 3 to 4 months. The half-life of passively acquired maternal immunoglobulins was around 6 weeks. Based on a large number of subjects, this study clearly demonstrated, for the first time in France, high levels of passively acquired maternal antibodies during the neonatal period, and it allowed us to estimate the duration of passively acquired maternal anti-VZV IgG in French infants. After 4 to 5 months, infants had very low levels of maternal anti-VZV IgG, below the 150-mIU/ml cutoff of the VZV IgG TRFIA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176690      PMCID: PMC2668269          DOI: 10.1128/CVI.00397-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  Seroprevalence of varicella in the French population.

Authors:  Babak Khoshnood; Monique Debruyne; Florian Lançon; Corinne Emery; Francis Fagnani; Isabelle Durand; Daniel Floret
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

2.  Paediatric varicella hospitalisations in France: a nationwide survey.

Authors:  E Grimprel; C Levy; F de La Rocque; R Cohen; B Soubeyrand; E Caulin; T Derrough; A Lecuyer; P d'Athis; J Gaudelus
Journal:  Clin Microbiol Infect       Date:  2007-03-22       Impact factor: 8.067

3.  Placental transfer and decay of varicella-zoster virus antibodies in preterm infants.

Authors:  N Linder; I Waintraub; Z Smetana; A Barzilai; D Lubin; E Mendelson; L Sirota
Journal:  J Pediatr       Date:  2000-07       Impact factor: 4.406

4.  Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.

Authors:  Ulrich Heininger; Daniel Desgrandchamps; Urs B Schaad
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

5.  The economic value of childhood varicella vaccination in France and Germany.

Authors:  Laurent Coudeville; Alain Brunot; Thomas D Szucs; Benoit Dervaux
Journal:  Value Health       Date:  2005 May-Jun       Impact factor: 5.725

6.  The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France.

Authors:  L Coudeville; F Paree; T Lebrun; J Sailly
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

7.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

8.  Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection.

Authors:  P A Chris Maple; Jim Gray; Kevin Brown; David Brown
Journal:  J Virol Methods       Date:  2009-01-23       Impact factor: 2.014

9.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Seroprevalence of varicella antibodies among pregnant women in Lyon-France.

Authors:  M Saadatian-Elahi; Y Mekki; C Del Signore; B Lina; T Derrough; E Caulin; J Thierry; P Vanhems
Journal:  Eur J Epidemiol       Date:  2007-05-30       Impact factor: 12.434

View more
  7 in total

1.  Determining the persistence of maternally acquired antibodies to hepatitis A and varicella zoster during the first 2 years of life in Turkey.

Authors:  Fırat Begde; Filiz Simsek Orhon; Devran Gerceker; Betul Ulukol; Seda Topcu; Sevgi Baskan
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

2.  Waning immunity to varicella in infants of human immunodeficiency virus-seropositive and -seronegative mothers.

Authors:  Shahana A Choudhury; Gwinnett Ladson; Edward R Hills; Frank Hatcher
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

3.  Varicella susceptibility and transmission dynamics in Slovenia.

Authors:  Maja Socan; Natasa Berginc; Jaro Lajovic
Journal:  BMC Public Health       Date:  2010-06-23       Impact factor: 3.295

4.  Modelling the effects of population structure on childhood disease: the case of varicella.

Authors:  Romain Silhol; Pierre-Yves Boëlle
Journal:  PLoS Comput Biol       Date:  2011-07-21       Impact factor: 4.475

5.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

6.  Modeling the impact of changes in day-care contact patterns on the dynamics of varicella transmission in France between 1991 and 2015.

Authors:  Valentina Marziano; Piero Poletti; Guillaume Béraud; Pierre-Yves Boëlle; Stefano Merler; Vittoria Colizza
Journal:  PLoS Comput Biol       Date:  2018-08-01       Impact factor: 4.475

7.  Hospitalization of newborns and young infants for chickenpox in France.

Authors:  Aurélie Lécuyer; Corinne Levy; Joel Gaudelus; Daniel Floret; Benoit Soubeyrand; Evelyne Caulin; Robert Cohen; Emmanuel Grimprel
Journal:  Eur J Pediatr       Date:  2010-05-12       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.